Nabriva Therapeutics appoints Dr. Colin Broom as Chief Executive Officer

Dr Denise Pollard-Knight, Chairman of the Supervisory Board of Nabriva, commented on the appointment:
“We welcome Colin to Nabriva and are delighted to announce the opening of our US subsidiary. Colin’s track record and experience will enable us to maximise the potential in Nabriva's pipeline. The increasing interest in the development of new antibiotics and a favourable funding environment for biotech companies in the US provide a great opportunity to position the company for significant growth in the future. “I would like to take this opportunity to thank Ralf Schmid, the current CEO who is assuming the roles of COO and CFO. Ralf has been instrumental in establishing Nabriva and leading us to this important stage, and will in his new role head the Austrian site and continue to play a key role in the company’s future development.”

Dr Broom, newly appointed Chief Executive Officer of Nabriva, added:
“New antibiotic development is one of the most important priorities in medicine as we see increasing resistance to currently available drugs. Nabriva is one of a few development stage companies with a truly novel antibiotic product ready for Phase 3 studies in an area of significant unmet medical need, and with a clear development path to potential approval. I am very excited to join Nabriva at this stage and look forward to working with the highly ex perienced board and management team on building a patient-centric global biopharmaceutical company. My immediate attention is focussed on establishing a world-class clinical development team in the Philadelphia area.” Dr Broom has worked in biopharmaceutical drug development and commercialization for 30 years. Most recently he served as Chief Scientific Officer at ViroPharma, Inc., which was acquired by Shire plc for $4.2bn in January 2014. Prior development roles included senior positions at Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline). Dr Broom also serves on the board of NPS Pharmaceuticals. Dr Broom holds a Bachelor of Science degree in pharmacology from University College, London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George’s Hospital Medical School, London. He is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.